Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$1.30M+70.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew Obenshain
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 77
- Beta
- 0.91
- Country
- FR
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.29
Financials
Revenue
$1.30M+70.3%Net Income
$-70.40MEBITDA
$-70.71MFree Cash Flow
$-59.06MEPS (diluted)
$-0.26Shares Outstanding (diluted)
273.58M+2627.6%Operating Expenses
$69.78MCash & Debt
$166.06MReturn of Capital
$50.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.48M | $-340.16M | $-1.82 |
| 2024 | $9.20M | $-184.21M | $-3.54 |
| 2023 | $17.48M | $-110.43M | $-2.43 |
| 2022 | $12.18M | $-54.27M | $-1.31 |
| 2021 | $4.19M | $-49.64M | $-1.27 |
| 2020 | $372.0K | $-33.62M | $-0.99 |
| 2019 | $7.00M | $-30.22M | $-1.28 |
| 2018 | $3.20M | $-33.62M | $-1.64 |
| 2017 | $6.52M | $-17.23M | $-1.11 |
| 2016 | $9.45M | $-7.05M | $-0.45 |
| 2015 | $4.87M | $-8.82M | $-0.88 |
| 2014 | $3.28M | $-7.49M | $-0.75 |
| 2013 | $3.06M | $-7.13M | $-0.71 |
Valuation
IVAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (6)
- Newsmarketbeat.com·2d ago·Neutral
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.
View source ↗ - Newsdefenseworld.net·5d ago·Neutral
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.14 Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have given a strong buy recommendation to the
View source ↗ - Newsbenzinga.com·7d ago·Neutral
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
View source ↗ - Newsseekingalpha.com·7d ago·Positive
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·7d ago·Neutral
Inventiva Q2 Earnings Call Highlights Inventiva NASDAQ: IVA said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study's 72-week visit earlier this month.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗
Earnings
Wed, Mar 31(in 6 months)
Consensus estimate $-0.33 per share
Typical surprise -211.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 28$-0.28 vs $-0.20miss
- Mon, Mar 30$-1.07 vs $-0.23miss
- Thu, Sep 25$-1.89 vs $-0.41miss
- Wed, Mar 26$-2.19 vs $-0.44miss
- Wed, Sep 25$-1.01 vs $-0.56miss
- Wed, Mar 27$-1.25 vs $-0.40miss
Estimates and results for IVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in IVA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.